安维汀疗效和安全性回顾和进展医学课件.ppt

谢 谢！ 既往未治疗的 IIIB-IV期 非鳞癌NSCLC PS 0-1 (n=939) 培美曲塞 N=359 安慰剂 N=180 培美曲塞 + 顺铂 CR/PR/SD R 2 1 PARAMOUNT 研究设计 AVAPERL 一线诱导4周期, q3w 维持维持治疗 q3w 直至PD 既往未治疗的 IIIB-IV期 非鳞癌NSCLC PS 0-1 (n=374) 贝伐珠单抗 N=124 贝伐珠单抗 + 培美曲塞 N=128 贝伐珠单抗 + 培美曲塞 + 顺铂 CR/PR/SD R 1 1 最佳总体疗效 PARAMOUNT AVAPERL入组的所有患者 Barlesi, et al. ECCO-ESMO 2011 Paz-Ares, et al. ASCO 2011 患者 (%) 客观缓解率 绝对差异 10% 2/3的患者疾病稳定 自诱导阶段的PFS * 培美曲塞: 6.9m 安慰剂: 5.6m HR: 0.59, P0.001 3 6 9 12 15 3 6 9 12 15 贝伐珠单抗+ 培美曲塞: 10.2m 贝伐珠单抗: 6.6m HR: 0.50, P0.001 时间 (月) 100 75 50 25 0 时间 (月) AVAPERL PARAMOUNT 100 75 50 25 0 Δ 3.6个月 Δ 1.3个月 AVAPERL: Barlesi, et al. ECCO-ESMO 2011 PARAMOUNT: Paz-Ares, et al. ASCO 2011 * * This slide shows the study design for the E4599 phase III trial of carboplatin/paclitaxel with or without Avastin as first-line therapy for NSCLC. This was a multicentre randomised trial carried out by the Eastern Cooperative Oncology Group (ECOG) in 78 sites in the USA, Puerto Rico and South Africa. Randomisation was stratified by measurability of disease (yes or no), disease stage (IIIB/IV/recurrent), presence or absence of prior radiation therapy, and amount of prior weight loss (≧5% or 5%) Patients were treated until disease progression (as assessed by the investigator) or unacceptable toxicity. Patients in the CP-alone arm were not permitted to cross over to receive Avastin at disease progression. Reference Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Eng J Med 2006;355:2542-50. Among the 878 patients randomised, 698 deaths had occurred at the time of the final analysis. The Kaplan-Meier curve shown here demonstrates the effect of adding Avastin to CP on overall survival.1 A significant increase in median overall survival was observed in patients receiving Avastin + CP compared with CP alone(12.3 months vs 10.3 mon